The frequency of infection with the six classified major genotypes of hepatitis C virus (HCV) was investigated in 447 infected volunteer blood donors from the following nine countries: Scotland, Finland, The Netherlands, Hungary, Australia, Egypt, Japan, Hong Kong, and Taiwan. Viral sequences in plasma from blood donors infected with HCV were amplified in the 5'-noncoding region and were typed by restriction fragment length polymorphism analysis. Electrophoresis of DNA fragments produced by cleavage with HaeIII-RsaI and ScrFI-Hinfl allowed HCV types 1 (or 5), 2, 3, 4, and 6 to be identified. Further analysis with MvaI-Hinfl allowed sequences of the type 5 genotype to be distinguished from sequences of the type 1 genotype. Types 1, 2, and 3 accounted for almost all infections in donors from Scotland, Finland, The Netherlands, and Australia. Types 2 and 3 were not found in the eastern European country (Hungary), where all but one of the donors were infected with type 1. Donors from Japan and Taiwan were infected only with type 1 or 2, while types 1, 2, and 6 were found in those from Hong Kong. HCV infection among Egyptians was almost always by type 4 . Donors infected with HCV type 1 showed broad serological reactivity with all four antigens of the second generation Chiron RIBA-2 assay (Chiron Corporation, Emeryville, Calif.), while infection with divergent HCV genotypes elicited antibodies mainly reactive to c22-3 and c33c. Reactivities with antibodies 5-1-1 and clOO-3 were infrequent and were generally weak, irrespective of the geographical origin of the donor. Because the envelope region of HCV is even more variable than the NS-4 region, it is likely that vaccines based on these proteins need to be multivalent and perhaps specifically adapted for different geographical regions.
The discovery of hepatitis C virus (HCV) (6) and the development of serological screening assays for HCV antibody in blood donors has provided a valuable method for the prevention of posttransfusion non-A, non-B hepatitis. The original anti-HCV enzyme immunoassay (EIA) used a recombinant protein, clOO-3, derived from the NS-4 region of the viral genome as the solid-phase antigen in an indirect enzymelinked immunosorbent assay (ELISA) and proved to be capable of detecting most, but not all, blood donations implicated in the transmission of HCV to recipients (12, 14) . Secondgeneration ELAs include recombinant antigens from the core and NS-3 regions of HCV and are capable of detecting HCV antibody in blood donors and hemophiliacs at much higher rates (1) . However, some HCV-infected blood donors may not be detected because of the delay between primary infection and seroconversion to positivitv for antibody to HCV. Alternatively, infection with HCV isolates with sequences divergent from those of the prototype virus may elicit antibodies that do not cross-react with the antigens used in current screening assays.
Comparison of the complete genomic sequences of HCV reveals considerable heterogeneity between different isolates. For example, the prototype virus (HCV-1) (8) and HCV type HC-J6 (22) show a 33% nucleotide sequence divergence that is distributed throughout the genome in regions encoding both structural and nonstructural proteins (21) . Divergence is most extreme for the envelope proteins and the part of the NS-4 gene that codes for the clOO-3 antigen, with only 50% predicted amino acid sequence identity between different HCV genotypes.
HCV has been classified into a number of distinct groups or genotypes on the basis of the sequence similarities of complete genomic sequences (21) or fragments amplified by PCR (3, 4, 11, 19) . Unfortunately, there are at least three different classification systems in the literature, and this has caused confusion and difficulty when results from different research groups are compared. However, several laboratories studying viral sequence variation have agreed upon a standardized system of HCV nomenclature (25) that reflects the two-titered nature of sequence variability. All known variants can be classified into a total of six major genotypes (types 1 to 6), of 884 Vol. 32, No. 4 GEOGRAPHICAL DISTRIBUTION OF HCV GENOTYPES 885 which four (types 1 to 4) contain several more closely related subtypes (e.g., a, b, and c).
Variants previously described as belonging to types or groups I and 11 (3, 13, 19, 21) are designated types la and lb. The more divergent HCV types, such as HC-J6 and HC-J8 (21, 22) , are designated types 2a and 2b, respectively. Variants described as type 3 (4), type IV (3), or types V and VI (19) (25) .
The six major genotypes have distinct nucleotide sequences in the 5'-NCR (2, 26) , and so viruses can be typed by restriction fragment length polymorphism (RFLP) analysis of DNA amplified from that region of the viral genome by reverse transcription and then PCR (18, 20 Samples from Japan were screened by anti-HCV passive hemagglutination assay by using erythrocytes coated with PHCV-34 and PHCV-31 antigens (Dainabot Co. Ltd., Abbott, Japan). Samples from Taiwan were screened by using a second-generation ELISA with HCV antigens equivalent to c22-3, c33c, and c100-3.
Donations from Finland, The Netherlands, Hungary, Australia, and Egypt that were repeatedly reactive on screening by the Abbott or the Ortho second-generation assays were tested further by the RIBA-2 assay (Chiron Corporation, Emeryville, Calif.) (see Table 1 ). Samples that were confirmed to be positive (significant reactivity with two or more recombinant antigens) or indeterminate (reactivity with one antigen) were shipped frozen to Edinburgh for further analysis by PCR. In Hong Kong, the Abbott Matrix assay was used for supplementary testing. Samples from Japanese donors that were reactive on screening and that showed titers of >212 in the HCV passive hemagglutination assay were referred to Edinburgh, while those from Taiwanese donors were referred without prior confirmatory testing. In interpreting the RIBA-2 assay results, we considered that reactivities with the 5-1-1 and c100-3 antigens do not represent true confirmation of positive results, since both antigens are derived from the same region of NS-4 and could be reacting with the same epitope in both proteins. In the present study, samples showing this type of dual reactivity were considered indeterminate (see Table 4 ). HCV typing. RNA PCR was carried out as described previously (4) by using primers matching conserved regions in the 5'-NCR. The PCR assay has proved to be both sensitive and specific for the detection of HCV RNA sequences in plasma (9) . To monitor possible contamination with exogenous sequences during extraction or setting up of the amplification reactions, RNAs from at least three negative control plasma samples were extracted, reverse transcribed, and amplified in each batch of donor samples examined by PCR. On no occasion were false-positive results obtained with these negative controls. The PCR product was radiolabelled by the addition of [35S]dATP in the second PCR stage. Two aliquots of product DNA were cleaved with HaeIII-RsaI, ScrFI-Hinfl, or MvaI-Hinfl as described previously (18) , and the DNA fragments were electrophoresed on a high-resolution (nondenaturing) polyacrylamide gel that allowed fragments of 30 to 500 bp to be resolved.
The nomenclature for the bands produced by HaeIII-RsaI and ScrFI-Hinfl broadly follows that described previously (18) , but with additional patterns for genotypes 4 and 6. For simplicity, the two patterns with ScrFI (ScrFI-Hinfl) which were not distinguishable (patterns A and B) by electrophoresis are referred to here as pattern A. Similarly, a rare C-*T change found in type 3 and type 4 sequences at position -220 (e.g., E-bl [4] and EG-33 [26] ) creates a new Hinfl site, but the position of cleavage is 3 bp downstream from a conserved ScrFI or MvaI site. Because these two sites could not be cleaved simultaneously, the polymorphism would not affect the overall band patterns. Since there are no other variable Hinfl or ScrFI sites in type 3 and 4 sequences, we assigned a single letter (G and H, respectively) to each sequence.
Nucleotide sequencing. To investigate samples showing unusual electropherotypes (n = 2) or to confirm the identities of samples showing unexpected distributions (n = 3), the 5'-NCR was amplified with unlabelled nucleotide triphosphates and directly sequenced by using both sense and antisense inner primers as described previously (4).
New sequences described in this report have been submitted to GenBank (accession numbers L28057 and L28058). RESULTS HCV typing method. The predicted cleavage patterns of sequences corresponding to the region in the 5'-NCR amplified by PCR varied considerably among the different major types of HCV (Fig. 1) . By using the combination HaeIII-RsaI, patterns designated a and b were predicted for published type 1, type 4, and type 5 sequences, while patterns designated c, d, and e were uniquely associated with type 2 (Fig. 1A) . Patterns f and g should be produced by all known type 3 sequences, and pattern h should be produced by all known type 6 sequences. The latter pattern differed from pattern d (type 2) by the two insertions (a total of 3 bp) in the 114-bp fragment. This size difference can readily be resolved by polyacrylamide gel electrophoresis of the cleaved DNA.
The second set of restriction enzymes (ScrFI-Hinfl) produced different bands for five of the six HCV genotypes (Fig.  IB) . For type 6 sequences, a 3-bp insertion in the 35-bp fragment (pattern I) distinguished them from type 1 sequences (pattern A; 32 bp). With neither combination of enzymes was it possible to distinguish type 5 from type I sequences. However, these two genotypes can be reliably differentiated by using MvaI-Hinfl (Fig. IC) , in which of a total of four possible electropherotypes, all type 1 sequences produce pattern A and all type 5 sequences produce pattern D. These enzymes also distinguish many of the other genotypes, and in principle, it would be possible to identify all six by cleavage with HaeIIIRsaI in one reaction and by cleavage with MvaI-Hinfl in the other.
Identification of HCV genotypes in blood donors. Viral RNA sequences could be amplified from a total of 421 of the 526 RIBA-2 assay-positive samples from volunteer blood donors (80%) and from 26 of the 430 RIBA-2 assay-indeterminate samples (6%) ( Table 1 ). The incidence of confirmed HCV infection (samples that were either RIBA-2 assay positive or PCR positive) varied from 0.01% (Finland, The Netherlands) to more than 8% (Egypt).
Amplified sequences from each of the 447 PCR-positive samples were typed by RFLP analysis by using the restriction endonucleases HaeIII-RsaI and ScrFI-Hinfl (Table 2) . A wide range of electrophoretic patterns was found in the study samples, but almost all could be assigned to those predicted for published sequences (n = 443; Table 2 ). In no case were there incompatible combinations of RFLP patterns between the two sets of enzymes ( Fig. 2A) , and sequences from all 443 samples could be assigned to types 1 (type 5), 2, 3, 4, and 6. Because sequences of genotype 5 produce the same RFLP patterns as ' The first letter (lowercase a to h) indicates the cleavage pattern observed upon digestion with HaeIIl-RsaI (Fig. IA) . The second letter (capital A to 1) refers to the cleavage pattern observed upon digestion with ScrFI-Hi,zfl (Fig. IB) Serological reactivity. Irrespective of the geographical origins of the donors, sera from those infected with HCV type 1 showed broad reactivities with all four antigens in the secondgeneration RIBA-2 assay, with a high mean score in all cases ( Fig. 3 ; Table 4 ). The antibody response elicited by infection with HCV types 2, 3, 4, and 6 showed reactivity that was largely restricted to c33c and c22-3 antigens (Fig. 3) . Reactivity to the 5-1-1 antigen was found in 79, 17, 7, 42, and 33% of donors infected with types 1, 2, 3, 4, and 6, respectively, and reactivity to the clOO-3 antigen was found in 78, 34, 33, 58, and 58%, respectively (Table 4 ). There was a significant difference between the proportion of type 1 samples that were reactive with antigen 5-1-1 compared with the proportion of samples of the other four genotypes that were reactive with antigen 5-1-1, either individually (type 2, P < 0.0001; type 3, P < 0.0001; type 4, P < 0.001; type 6, P < 0.001) or collectively (X2 = 176; 4 degrees of freedom on a 2-by-2 contingency table; P < 0.0001). There were also significant differences between type 1 and types 2, 3, 4, and 6 in the frequency of reactivity to antigen clOO-3 (P < 0.0001, P < 0.0001, P < 0.05, and P 0.1 for types 2, 3, 4, and 6, respectively). Between type 1 and the four genotypes together, there was a highly significant difference (X2 = 82; 4 degrees of freedom; P < 0.0001).
Only 26 of 430 (6%) RIBA-2 assay-indeterminate samples were PCR positive, whereas 421 of 526 (80%) samples confirmed to be positive by the RIBA-2 assay were PCR positive Confirmed by RIBA-2  assay  +  +  +  +  271  222  187  15  5  8  0  4  1  2  +  -+  +  19  12  12  0   0  0  0  0  0  0  -+  +  +  70  50  10  14  19  3  1  3  0  0  --+  +  166  137  33  56  35  7  0  5   1   0   Subtotal  526  421  242  85  59  18  1  12  2  2 Indeterminate by RIBA-2 assay + --- Samples showing reactivities to proteins 5-1-1 and clt)t)-3 were not considered confirmed for the reasons described in the text.
( Table 4 ). All samples that were indeterminate and that were reactive with the NS-4-derived proteins clOO-3 or 5-1-1 were PCR negative, while a significant proportion of those showing an indeterminate reaction with the c33c or c22-3 antigen were PCR positive (2 of 24 and 23 of 339 samples, respectively). Approximately 20% of samples from donors infected with type 3 were reactive with c22-3 only, whereas 3% of samples from those infected with type 1 were reactive with c22-3 only (X2 = 23; P < 0.0001). However, sequence variability was not the only cause of restricted serological reactivity, because many of the samples that failed to react with antigens clOO-3 and 5-1-1 were obtained from donors infected with type 1 (10 of 430 RIBA-2 assay-indeterminate samples and 33 of the 166 samples that were reactive with antigens c22-3 and c33c only). We are analyzing whether this restricted pattern of reactivity is associated with proximity to seroconversion by testing previous donations and follow-up samples from the donors. From retrospective testing, we found that the type 1-infected donor whose sera reacted with antigen c33c only (Table 4) showed a similar serological profile for at least 2 years (data not shown). DISCUSSION In the study described here, we modified an existing typing assay so that all six known major genotypes of HCV could be recognized. By the addition of Hinfl to ScrFI, a novel site present in all type 4 (and type 3) variants resulting from a change from U to C at position -166 could be recognized. New cleavage patterns resulting from the 3-base insertion in the 5'-NCR of type 6 variants were also classified in the study as electropherotype h with HaeIII-RsaI and electropherotype I with ScrFI-Hinfl. The type 5 sequences could be distinguished from type 1, replacing ScrFI (GGnCC) with MvaI (GG[A/ T]CC) to identify the A/G polymorphism at position -162 and the U/C polymorphism at position -121. We are in the process of exploring whether MvaI-Hinfl can be used to entirely replace the original ScrFI-Hinfl combination for the identification of all six genotypes, as suggested by analysis of the predicted fragment patterns of the published sequences ( Fig. IA and C) .
The (11, 28, 31) .
There is now a considerable amount of comparative sequence data on the 5'-NCRs of HCV types 1, 2, and 3 from several geographical regions. It is therefore possible to predict a comprehensive range of possible electropherotypes with the restriction enzymes used in the present study and to reliably differentiate these genotypes from each other. However, the designation of specific electropherotypes to HCV types 4, 5, and 6 is preliminary at this stage because so few sequences in the 5'-NCR have been described. For example, the existence of types 4, 5, and 6 is based on phylogenetic analysis of 3, 4, and 1 sequences, respectively, in the NS-5 region (25) . Each of these new genotypes contains sequences that are distinct in the 5'-NCR, and to date, a total of 18, 6, and 6 5'-NCR sequences similar to those of types 4, 5, and 6 that have been definitively genotyped have been published (2, 26) . It is likely that a wider range of electropherotypes will be found for these genotypes, and continuous modification of Fig. 1 (10) and is associated with a much poorer response to treatment with alpha interferon than are type 2 (15, 29, 33) and type 3 (10) . It is perhaps significant that among the asymptomatic blood donors in the present study, we found a much higher rate of non-type 1 variants (43%) than in previous surveys (20, 23, 30, 31) .
Any attempt to interpret these geographical differences is hampered by current ignorance surrounding the method of virus transmission. Needle sharing, transfusion of blood and blood products, tattooing, and other forms of parenteral exposure have been implicated in the transmission of HCV, while current evidence suggests that the intrafamilial, motherto-child, sexual, and intrafamilial forms of transmission are relatively inefficient modes of virus spread. There The existence of variants of HCV that show up to 30% sequence diversity could potentially lead to significant antigenic variations among homologous proteins encoded by the different genotypes of HCV. The effects that this sequence variation would have on the effectiveness of antibody screening for HCV remains a relatively unexplored area. All currently used assays use antigens derived from HCV type 1 sequences and rely on cross-reacting antibodies to detect infection with other HCV genotypes. This is illustrated by the first-generation assays that used the clOO-3 recombinant protein derived from NS-4. The antigenic region was found to be particularly variable in sequence between HCV types 1, 2, and 3 (27) and led to a low rate of detection of infection with variants other than type 1 (5, 18) . In the present study, we showed that the majority of individuals infected with genotypes 2 to 6 showed weak or absent reactivity to c100-3, confirming our previous observations for types 2 and 3 on a relatively smaller number of individuals (18) . This lack of cross-reactivity provides at least one explanation for the continuing transmission of HCV by blood screened by anti-CIOO assays alone (12, 14) .
All donors infected with HCV types 2 to 6 reacted with the recombinant core protein c22-3, probably reflecting the protein's greater degree of amino acid sequence conservation (90%) than that among the nonstructural proteins (75 to 80%). However, this observation is misleading, because c22-3 is a component of screening and confirmatory assays for HCV infection. In interpreting these results, the preselection by the screening assays precluded an analysis of the proportion of donors with infections with divergent HCV types that elicited an even more restricted serological response so as to be undetectable by current blood donor screening assays. The actual frequency with which samples from individuals infected with variants other than type 1 are missed by current secondgeneration screening assays (which contain c33c and c22-3 as well as NS-4 proteins) is unknown, but it is probably low. However, it is recognized that the serological response to HCV-encoded antigens is often narrow in specificity and is generally of low titer. Acute infections with HCV following transfusion of infectious blood or blood products may fail to elicit antibodies for several months (32 (23, 27) . These 
